Get the Stockscreener App
12.29
6.79%
-0.895
After Hours:
12.28
-0.005
-0.04%
Syndax Pharmaceuticals Inc stock is traded at $12.29, with a volume of 2.50M.
It is down -6.79% in the last 24 hours and down -21.45% over the past month.
See More
Previous Close:
$13.18
Open:
$12.85
24h Volume:
2.50M
Relative Volume:
1.24
Market Cap:
$1.18B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-4.1503
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
-10.52%
1M Performance:
-21.45%
6M Performance:
-36.18%
1Y Performance:
-48.38%
1-Day Range:
$12.12
$12.98
1-Week Range:
$12.12
$13.80
52-Week Range:
$12.06
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
35 GATEHOUSE DRIVE, WALTHAM, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
12.29 | 1.18B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Simplify Asset Management Inc. Purchases 25,456 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
What Do Analysts Think About Syndax Pharmaceuticals Inc’s (NASDAQ:SNDX) Future? - Stocks Register
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $41.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Long Term Trading Analysis for (SNDX) - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Purchases 8,876 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 5.5% Following Analyst Upgrade - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $41.00 - Defense World
Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call By Investing.com - Investing.com UK
Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth - Benzinga
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 5.5% on Analyst Upgrade - Defense World
Bank of New York Mellon Corp Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
US Bancorp DE Reduces Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.00 Average Price Target from Analysts - MarketBeat
Syndax at Barclays Healthcare Conference: Strategic Vision for Menin Inhibitors - Investing.com UK
Syndax Pharmaceuticals’ SWOT analysis: stock soars on FDA approvals, faces profitability hurdles - Investing.com India
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Syndax Pharmaceuticals’ SWOT analysis: stock soars on FDA approvals, faces profitability hurdles By Investing.com - Investing.com South Africa
Graft Versus Host Disease Market Expected to rise, 2034 | Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio - The Globe and Mail
Candriam S.C.A. Cuts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
What Does Syndax Pharmaceuticals Inc’s (NASDAQ: SNDX) Future Hold? - Stocks Register
What is B. Riley's Forecast for SNDX Q3 Earnings? - MarketBeat
What is HC Wainwright's Forecast for SNDX FY2025 Earnings? - MarketBeat
What is HC Wainwright's Forecast for SNDX Q1 Earnings? - MarketBeat
Q1 Earnings Forecast for SNDX Issued By B. Riley - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.4% Following Weak Earnings - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
Citigroup Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Syndax Pharmaceuticals Reports 2024 Financial Results - MSN
Syndax Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
What is B. Riley’s Estimate for SNDX Q3 Earnings? - Defense World
What is HC Wainwright’s Forecast for SNDX FY2025 Earnings? - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results - MarketBeat
Strong Buy Rating for Syndax Pharmaceuticals Driven by Revuforj’s Market Potential and Revenue Growth - TipRanks
HC Wainwright Reiterates “Buy” Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
What is B. Riley’s Forecast for SNDX Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for SNDX Q1 Earnings? - Defense World
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... By GuruFocus - Investing.com Canada
Syndax Pharmaceuticals’ Earnings Call Highlights Key Milestones - TipRanks
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):